Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

NCT05281718 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: Factor IX

Sponsor

Tulane University

Collaborators

[object Object]